中国医学创新
中國醫學創新
중국의학창신
Medical Innovation of China
2015年
31期
32-34,35
,共4页
王先国%周远%李宇%张山燕%陈景华
王先國%週遠%李宇%張山燕%陳景華
왕선국%주원%리우%장산연%진경화
非小细胞肺癌%培美曲塞%替吉奥胶囊%老年人
非小細胞肺癌%培美麯塞%替吉奧膠囊%老年人
비소세포폐암%배미곡새%체길오효낭%노년인
Non-small cell lung cancer%Pemetrexed%Tegafur gimeracil oteracil potassium capsule%Elderly
目的：探讨培美曲塞联合替吉奥方案治疗晚期老年非小细胞肺癌的临床疗效。方法：将50例老年晚期非小细胞肺癌患者按随机数字表法分为治疗组和对照组。治疗组25例，给予培美曲赛+替吉奥方案化疗，对照组25例，给予最佳支持治疗（best supportive care， BSC）。观察两组治疗结束后3个月的近期疗效、1年和2年生存率及不良反应。结果：治疗结束后3个月，治疗组的客观有效率为48.0%，对照组为8.0%，两组比较差异具有统计学意义（P=0.002）。治疗组和对照组的1、2年生存率分别为41.7%、4.2%和29.2%、0，两组比较差异有显著统计学意义（P<0.001）。治疗组的毒副反应主要为骨髓抑制（白细胞下降、贫血、血小板下降）、肝肾功损伤，对照组未出现明显毒副反应。结论：培美曲塞联合替吉奥方案治疗晚期老年非小细胞肺癌可提高近期疗效及1、2年生存率，可作为老年晚期非小细胞肺癌的一种安全、有效的治疗方法。
目的：探討培美麯塞聯閤替吉奧方案治療晚期老年非小細胞肺癌的臨床療效。方法：將50例老年晚期非小細胞肺癌患者按隨機數字錶法分為治療組和對照組。治療組25例，給予培美麯賽+替吉奧方案化療，對照組25例，給予最佳支持治療（best supportive care， BSC）。觀察兩組治療結束後3箇月的近期療效、1年和2年生存率及不良反應。結果：治療結束後3箇月，治療組的客觀有效率為48.0%，對照組為8.0%，兩組比較差異具有統計學意義（P=0.002）。治療組和對照組的1、2年生存率分彆為41.7%、4.2%和29.2%、0，兩組比較差異有顯著統計學意義（P<0.001）。治療組的毒副反應主要為骨髓抑製（白細胞下降、貧血、血小闆下降）、肝腎功損傷，對照組未齣現明顯毒副反應。結論：培美麯塞聯閤替吉奧方案治療晚期老年非小細胞肺癌可提高近期療效及1、2年生存率，可作為老年晚期非小細胞肺癌的一種安全、有效的治療方法。
목적：탐토배미곡새연합체길오방안치료만기노년비소세포폐암적림상료효。방법：장50례노년만기비소세포폐암환자안수궤수자표법분위치료조화대조조。치료조25례，급여배미곡새+체길오방안화료，대조조25례，급여최가지지치료（best supportive care， BSC）。관찰량조치료결속후3개월적근기료효、1년화2년생존솔급불량반응。결과：치료결속후3개월，치료조적객관유효솔위48.0%，대조조위8.0%，량조비교차이구유통계학의의（P=0.002）。치료조화대조조적1、2년생존솔분별위41.7%、4.2%화29.2%、0，량조비교차이유현저통계학의의（P<0.001）。치료조적독부반응주요위골수억제（백세포하강、빈혈、혈소판하강）、간신공손상，대조조미출현명현독부반응。결론：배미곡새연합체길오방안치료만기노년비소세포폐암가제고근기료효급1、2년생존솔，가작위노년만기비소세포폐암적일충안전、유효적치료방법。
Objective:To investigate the clinical effect of pemetrexed combined with tegafur gimeracil oteracil potassium capsule for elderly patients with advanced non-small cell lung cancer.Method: 50 elderly patients with advanced non-small cell lung cancer were randomly divided into treatment group and control group. In the treatment group, 25 patients received pemetrexed + tegafur gimeracil oteracil potassium capsule chemotherapy. In the control group, 25 patients received best supportive care (BSC). Term efficacy, long-term survival and adverse reactions was compared between the two groups.Result: Two months after the end of treatment, the objective response rate of the treatment group and control group was 48.0% and 8.0%, respectively, there were statistically significant differences between the two groups (P=0.002). The 1, 2-year survival rates of the treatment group and the control group and was 41.7%, 4.2%, and 29.2%, 0, there was significant difference beween the two groups (P<0.001). The main toxicities in the treatment group was myelosuppression (leukopenia, anemia, thrombocytopenia), liver and kidney function damage, there was no obvious toxicity in the control group.Conclusion:Pemetrexed combined with tegafur gimeracil oteracil potassium capsule can improve the efficacy and 1,2-year survival rate, it can be used as a safe and effective method for elderly patients with advanced non-small cell lung cancer.
